ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2019 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones. “The first quarter of 2019 was a very productive start to the year, with strong execution across all aspects of our business,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis. “We continued our
Reported by Business Wire 11 hours ago.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2019 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones. “The first quarter of 2019 was a very productive start to the year, with strong execution across all aspects of our business,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis. “We continued our
Reported by Business Wire 11 hours ago.